DUSP5 Adaptive Feedback Limits DUSP4 Targeting Efficacy in Preclinical Cancer Models

In preclinical models of colorectal cancer and melanoma carrying the BRAF V600E mutation, genetically reducing the activity of the regulator protein DUSP4 slowed cancer cell proliferation and inhibited tumor growth, but an adaptive response involving the related protein DUSP5 restricted its therapeutic efficacy. The findings, reported in peer-reviewed research, indicate that compensatory cellular signaling can blunt the effectiveness of suppressing DUSP4 when evaluated as a monotherapy.

The study, titled “Limitation of the therapeutic potential of DUSP4 through adaptive feedback partially mediated by DUSP5,” was published in Volume 17 of Oncotarget on November 5, 2026. The investigation was co-first-authored by Barbara Hopfgartner and Monika Kriz, who contributed equally to the work, along with co-authors Donat Alpar, Yvonne Westermaier, Marco H. Hofmann, Ralph A. Neumüller, and Sarah Grosche, all affiliated with Boehringer Ingelheim RCV GmbH & Co KG in Vienna, Austria, with Neumüller and Grosche serving as corresponding authors.

Cancer cell survival and division rely on molecular signaling cascades, most notably the mitogen-activated protein kinase (MAPK) pathway, which is frequently dysregulated across diverse malignancies. Although standard therapeutic approaches predominantly focus on blocking excessive MAPK activity, investigators have also evaluated whether driving pathway signaling beyond tolerable physiological thresholds could disrupt cancer cell proliferation.

Within this regulatory framework, DUSP4 modulates the MAPK pathway by curbing the activity of downstream ERK proteins. In malignant cells harboring the BRAF V600E mutation, DUSP4 is thought to prevent excessive signaling from exceeding viable levels, rendering the protein an attractive candidate for targeted therapeutic disruption.

To explore this genetic vulnerability, the researchers analyzed DepMap Consortium database records using Chronos dependency scores, finding that cell lines dependent on DUSP4 and BRAF clustered within the BRAF V600E mutant group. Experimental CRISPR-mediated depletion of DUSP4 in BRAF V600E mutant COLO 201 colorectal cancer and HS695T melanoma cell lines resulted in marked proliferation defects, measured by green fluorescent protein (GFP) signal normalized to day 3 post-transduction across two biological replicates, whereas BRAF wild-type A549 cells exhibited no such defect.

The cell line models further demonstrated that BRAF V600E mutant lines remained dependent on DUSP4 even within a BRAF inhibitor-resistant setting, including cells resistant to dabrafenib. In rescue assays, the proliferation impairment caused by DUSP4 depletion was partially restored through DUSP4 overexpression and completely reversed by upstream MAPK pathway inhibition using 1 nM trametinib, while CRISPR depletion of the paralogs DUSP1, DUSP5, or DUSP6 produced no proliferation defects in COLO 201 or HS695T cells.

Mechanistic assessments confirmed that reducing DUSP4 activity elevated overall MAPK signaling across the tested colorectal cancer and melanoma models while slowing cellular growth. In the colorectal cancer lines, DUSP4 depletion directly triggered cell cycle arrest, halting normal progression into active cellular division.

The team extended these investigations in vivo by examining the effect of DUSP4 depletion in mice bearing colorectal tumors. Although tumor expansion was significantly inhibited compared to controls, the tumors remained largely stable rather than undergoing regression, and visible signs of tumor regrowth emerged over the course of the experiment, indicating that the cancer cells adapted to ongoing target inhibition.

Subsequent molecular analyses demonstrated that reducing DUSP4 prompted an upregulation of DUSP5, a related paralog that also regulates MAPK signaling. In follow-up cell experiments, elevated DUSP5 expression compensated for the absence of DUSP4 and restored cancer cell proliferation to varying degrees, demonstrating a mechanism of context-specific genetic buffering across DUSP family members.

The authors noted that because the study was conducted exclusively in preclinical cancer cell lines and mouse models, the findings do not establish clinical efficacy or performance in human patients. Consequently, the investigators concluded that while DUSP4 inhibition exhibits limited therapeutic efficacy as a standalone treatment, understanding DUSP5-mediated compensatory feedback will be essential for developing future signaling disruption strategies.

In the dependency mapping analysis utilizing data from the DepMap Consortium database, investigators evaluated gene dependency across the DUSP paralog family and BRAF. In this analysis, individual columns corresponded to specific genes while rows represented distinct cancer cell lines. Dependency Chronos scores were visualized across tiles ranging from red, indicating an absence of dependency, to blue, indicating dependency. Annotation bars distinguished the cellular genetic backgrounds, using dark turquoise to denote BRAF V600E mutant lines and grey to identify BRAF non-V600E mutation carrying lines, demonstrating that DUSP4 and BRAF dependencies were selectively enriched within the BRAF V600E mutant cluster.

Quantitative proliferation assays provided further resolution on cellular responses following DUSP4 CRISPR depletion across specific models. In BRAF V600E mutant COLO 201 colorectal cancer cells and HS695T melanoma cells, as well as BRAF wild-type A549 control cells, proliferation was tracked using green fluorescent protein (GFP) signal measurements normalized to day 3 post-transduction with DUSP4 CRISPR guides. Across two biological replicates, strong proliferation defects were confined exclusively to the BRAF V600E mutant cell lines, whereas the BRAF wild-type A549 line showed no such impairment. Furthermore, the experiments established that BRAF V600E mutant cell lines remained reliant on DUSP4 even in the presence of resistance to BRAF inhibition.

To dissect the specificity of the observed phenotype, researchers performed rescue experiments in the BRAF V600E mutant COLO 201 and HS695T cell lines. Following CRISPR-mediated DUSP4 depletion, cellular proliferation was measured by GFP signal normalized to day 3 post-guide transduction across two biological replicates under different intervention conditions. While ectopic DUSP4 overexpression achieved a partial rescue of cellular proliferation, pharmacological inhibition of the MAPK pathway upstream of DUSP4 using 1 nM trametinib resulted in a complete rescue of the proliferation defect, corroborating that the proliferative arrest stems from unrestrained pathway activity downstream.

The selectivity of this vulnerability was further examined by evaluating other members of the dual-specificity phosphatase family. CRISPR-mediated depletion of the related DUSP paralogs DUSP1, DUSP5, and DUSP6 was evaluated in both COLO 201 colorectal cancer and HS695T melanoma cell lines, with proliferation again quantified via GFP signal normalized to day 3 post-transduction. Unlike the depletion of DUSP4, the targeted knockdown of DUSP1, DUSP5, or DUSP6 produced no detectable proliferation defect in either cell line, confirming that the dependency among tested paralogs is specific to DUSP4 in this genetic context.

In animal studies assessing in vivo relevance, the researchers monitored tumor behavior in mice bearing colorectal tumors following DUSP4 reduction. Although the genetic intervention led to a statistically significant inhibition of overall tumor growth relative to controls, the tumors entered a state of relative stability rather than undergoing regression. Over the duration of the experimental observation period, signs of tumor regrowth emerged within the treated models, pointing to an adaptive capacity in cancer cells to circumvent sustained DUSP4 suppression.

Subsequent mechanistic investigations traced this adaptive resistance to the upregulation of DUSP5, a related dual-specificity phosphatase that similarly functions in regulating MAPK signaling cascades. Elevated levels of DUSP5 were shown to compensate for the reduction in DUSP4 activity, restoring cancer cell proliferation to varying degrees across cell experiments. As the authors observed, this phenomenon points to context-specific genetic buffering among DUSP proteins, wherein redundant regulatory mechanisms counteract the intended therapeutic disruption.

The authors emphasized the preclinical nature of the study, noting that the data are derived solely from cultured cancer cell lines and mouse xenograft models. Consequently, the findings do not determine how therapeutic strategies directed at DUSP4 would perform in human clinical settings. Given that DUSP5-mediated compensatory feedback restricts the therapeutic efficacy of DUSP4 inhibition when applied as a monotherapy, the researchers concluded that future therapeutic designs will require strategies that account for these adaptive feedback circuits to achieve effective and durable cancer growth control.

Subject of Research: Preclinical evaluation of DUSP4 inhibition and DUSP5 adaptive feedback in BRAF-mutant cancers

Article Title: DUSP5 feedback linked to limited therapeutic potential of DUSP4 in colorectal cancer

Article References: DUSP5 feedback linked to limited therapeutic potential of DUSP4 in colorectal cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: DUSP4, DUSP5, colorectal cancer, MAPK pathway, BRAF V600E, melanoma, targeted therapy, preclinical research, feedback, linked, limited, therapeutic